Literature DB >> 35601176

Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment.

Tie-Zhu Lin1,2, Emmanuel Eric Pazo2, Yue Ren2, Li-Jun Shen1,3.   

Abstract

Entities:  

Year:  2022        PMID： 35601176      PMCID： PMC9091876          DOI： 10.18240/ijo.2022.05.22

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  14 in total

1.  Choroidal neovascular membrane in Best's vitelliform macular dystrophy.

Authors:  S A Miller; G H Bresnick; S R Chandra
Journal:  Am J Ophthalmol       Date:  1976-08       Impact factor: 5.258

2.  Photodynamic therapy for best disease complicated by choroidal neovascularization in children.

Authors:  Sengul Ozdek; Mehmet Cuneyt Ozmen; Hasan Ali Tufan; Gokhan Gurelik; Berati Hasanreisoglu
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2011-10-11       Impact factor: 1.402

3.  Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.

Authors:  Gilda Cennamo; Ida Cesarano; Elisabetta Chiariello Vecchio; Michele Reibaldi; Giuseppe de Crecchio
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-28       Impact factor: 2.671

4.  Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child.

Authors:  Jay Chhablani; Subhadra Jalali
Journal:  Eur J Ophthalmol       Date:  2012 Jul-Aug       Impact factor: 2.597

Review 5.  Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

Authors:  Michael Tolentino
Journal:  Surv Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 6.048

6.  Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Neil M Bressler; Wesley T Beaulieu; Adam R Glassman; Kevin J Blinder; Susan B Bressler; Lee M Jampol; Michele Melia; John A Wells
Journal:  JAMA Ophthalmol       Date:  2018-03-01       Impact factor: 7.389

7.  Best vitelliform macular dystrophy in a Swedish family: genetic analysis and a seven-year follow-up of photodynamic treatment of a young boy with choroidal neovascularization.

Authors:  Christina I Frennesson; Claes Wadelius; Sven Erik G Nilsson
Journal:  Acta Ophthalmol       Date:  2013-04-26       Impact factor: 3.761

8.  Long-term evaluation of patients with Best's vitelliform dystrophy.

Authors:  C W Mohler; S L Fine
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

9.  Neovascularized Best Disease in Child: Contribution of Optical Coherence Tomography Angiography.

Authors:  Sandra Elbany; Laurent Kodjikian; Sophie Boucher; Olivier Loria; Carole Burillon; Thibaud Mathis
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-09-01       Impact factor: 1.300

10.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease.

Authors:  Rafael E Andrade; Michel E Farah; Rogério A Costa
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.